迈威（上海）生物科技有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
FDA Grants Fast Track Designation to 9MW3011 2023-09-22 08:00
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics 2023-09-08 15:30
Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023 2023-07-26 00:00
Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND 2023-07-22 00:00
Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND 2023-07-19 00:00
Mabwell Announces the U.S. FDA approval of 9MW3811 for IND 2023-06-15 21:00
Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal 2023-06-15 21:00
China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released 2023-04-07 16:34
The World's Second Approved Biosimilars of Denosumab (MAILISHU) 2023-04-03 13:44
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011 2023-03-14 23:42
First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND 2023-02-28 23:00
$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases 2023-01-20 09:50
Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries 2022-12-20 17:00
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND 2022-11-24 21:00
1 2